HomeCompareXVIPY vs PLD

XVIPY vs PLD: Dividend Comparison 2026

XVIPY yields 30.58% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.77M in total portfolio value· pulled ahead in Year 7
10 years
XVIPY
XVIPY
● Live price
30.58%
Share price
$6.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$136.9K
Annual income
$18,414.99
Full XVIPY calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — XVIPY vs PLD

📍 PLD pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXVIPYPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XVIPY + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XVIPY pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XVIPY
Annual income on $10K today (after 15% tax)
$2,599.39/yr
After 10yr DRIP, annual income (after tax)
$15,652.74/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,022,463.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XVIPY + PLD for your $10,000?

XVIPY: 50%PLD: 50%
100% PLD50/50100% XVIPY
Portfolio after 10yr
$3.02M
Annual income
$2,384,570.09/yr
Blended yield
78.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

XVIPY
No analyst data
Altman Z
4.9
Piotroski
6/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XVIPY buys
0
PLD buys
0
No recent congressional trades found for XVIPY or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXVIPYPLD
Forward yield30.58%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$136.9K$5.91M
Annual income after 10y$18,414.99$4,750,725.19
Total dividends collected$94.1K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: XVIPY vs PLD ($10,000, DRIP)

YearXVIPY PortfolioXVIPY Income/yrPLD PortfolioPLD Income/yrGap
1$13,758$3,058.10$11,241$540.96+$2.5KXVIPY
2$18,653$3,932.12$13,019$991.13+$5.6KXVIPY
3$24,941$4,982.42$15,801$1,870.97+$9.1KXVIPY
4$32,914$6,226.19$20,609$3,701.21+$12.3KXVIPY
5$42,896$7,678.77$29,919$7,867.97+$13.0KXVIPY
6$55,252$9,353.04$50,631$18,617.74+$4.6KXVIPY
7← crossover$70,379$11,258.95$105,528$51,352.20$35.1KPLD
8$88,708$13,403.14$287,364$174,449.42$198.7KPLD
9$110,707$15,788.69$1,081,760$774,280.77$971.1KPLD
10$136,871$18,414.99$5,908,209$4,750,725.19$5.77MPLD

XVIPY vs PLD: Complete Analysis 2026

XVIPYStock

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Full XVIPY Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this XVIPY vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XVIPY vs SCHDXVIPY vs JEPIXVIPY vs OXVIPY vs KOXVIPY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.